IBDEI2U7 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,47612,1,3,0)
 ;;=3^Extramedullary Plasmacytoma,In Remission
 ;;^UTILITY(U,$J,358.3,47612,1,4,0)
 ;;=4^C90.21
 ;;^UTILITY(U,$J,358.3,47612,2)
 ;;=^5001757
 ;;^UTILITY(U,$J,358.3,47613,0)
 ;;=C90.22^^209^2346^135
 ;;^UTILITY(U,$J,358.3,47613,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47613,1,3,0)
 ;;=3^Extramedullary Plasmacytoma,In Relapse
 ;;^UTILITY(U,$J,358.3,47613,1,4,0)
 ;;=4^C90.22
 ;;^UTILITY(U,$J,358.3,47613,2)
 ;;=^5001758
 ;;^UTILITY(U,$J,358.3,47614,0)
 ;;=C90.30^^209^2346^475
 ;;^UTILITY(U,$J,358.3,47614,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47614,1,3,0)
 ;;=3^Solitary Plasmacytoma,Not in Remission
 ;;^UTILITY(U,$J,358.3,47614,1,4,0)
 ;;=4^C90.30
 ;;^UTILITY(U,$J,358.3,47614,2)
 ;;=^5001759
 ;;^UTILITY(U,$J,358.3,47615,0)
 ;;=C90.31^^209^2346^474
 ;;^UTILITY(U,$J,358.3,47615,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47615,1,3,0)
 ;;=3^Solitary Plasmacytoma,In Remission
 ;;^UTILITY(U,$J,358.3,47615,1,4,0)
 ;;=4^C90.31
 ;;^UTILITY(U,$J,358.3,47615,2)
 ;;=^5001760
 ;;^UTILITY(U,$J,358.3,47616,0)
 ;;=C90.32^^209^2346^473
 ;;^UTILITY(U,$J,358.3,47616,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47616,1,3,0)
 ;;=3^Solitary Plasmacytoma,In Relapse
 ;;^UTILITY(U,$J,358.3,47616,1,4,0)
 ;;=4^C90.32
 ;;^UTILITY(U,$J,358.3,47616,2)
 ;;=^5001761
 ;;^UTILITY(U,$J,358.3,47617,0)
 ;;=C91.00^^209^2346^9
 ;;^UTILITY(U,$J,358.3,47617,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47617,1,3,0)
 ;;=3^Acute Lymphoblastic Leumkemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,47617,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,47617,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,47618,0)
 ;;=C91.01^^209^2346^8
 ;;^UTILITY(U,$J,358.3,47618,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47618,1,3,0)
 ;;=3^Acute Lymphoblastic Leumkemia,In Remission
 ;;^UTILITY(U,$J,358.3,47618,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,47618,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,47619,0)
 ;;=C91.02^^209^2346^7
 ;;^UTILITY(U,$J,358.3,47619,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47619,1,3,0)
 ;;=3^Acute Lymphoblastic Leumkemia,In Relapse
 ;;^UTILITY(U,$J,358.3,47619,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,47619,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,47620,0)
 ;;=C91.10^^209^2346^82
 ;;^UTILITY(U,$J,358.3,47620,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47620,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,47620,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,47620,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,47621,0)
 ;;=C91.11^^209^2346^83
 ;;^UTILITY(U,$J,358.3,47621,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47621,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,47621,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,47621,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,47622,0)
 ;;=C91.12^^209^2346^84
 ;;^UTILITY(U,$J,358.3,47622,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47622,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Relapse
 ;;^UTILITY(U,$J,358.3,47622,1,4,0)
 ;;=4^C91.12
 ;;^UTILITY(U,$J,358.3,47622,2)
 ;;=^5001767
 ;;^UTILITY(U,$J,358.3,47623,0)
 ;;=C91.30^^209^2346^446
 ;;^UTILITY(U,$J,358.3,47623,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47623,1,3,0)
 ;;=3^Prolymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,47623,1,4,0)
 ;;=4^C91.30
 ;;^UTILITY(U,$J,358.3,47623,2)
 ;;=^5001768
 ;;^UTILITY(U,$J,358.3,47624,0)
 ;;=C91.31^^209^2346^447
 ;;^UTILITY(U,$J,358.3,47624,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47624,1,3,0)
 ;;=3^Prolymphocytic Leukemia of B-Cell Type,In Remission
